AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Are ADCs having a moment? Is CAR-T safe? And who’s to blame for failed trials?…
Category: Medicine
STAT+: Radiology captures the tension between AI’s potential and concern for patients
Radiology has long led the way in the application of artificial intelligence in medicine. More…
Takeda, Janssen join wearable maker to measure scratching, and other health tech news
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology…
Do GLP-1s have a future treating alcoholism?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders
Rise and shine, everyone, another busy day is on the way. We can tell because…
.jpg)
STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion
AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring…
Opinion: Diagnostic tests for rare conditions present a mathematical conundrum
Worried about your health? You can now avail yourself of noninvasive diagnostics that claim to…
STAT+: Critics say HCA’s cost-cutting is endangering Appalachian patients — a warning for the whole U.S. health care system
ASHEVILLE, N.C. — There was the beeping of monitors, the stiff sheets, the sterile smell…
Opinion: How artificial intelligence could make pregnancy discrimination in employment more common
In June 2023, the Pregnant Workers Fairness Act (PWFA) went into effect. The federal law…
The surprising environmental cost of rapid testing, mosquito nets, and other lifesaving health products
Many commonly suggested ways to addressing climate change present few ethical challenges: Cut fossil fuels….
With latest tranche, U.K. Biobank has genome sequences from 500,000 people available for research
LONDON — Data from half a million people’s whole genome sequences are now available to…
.jpg)
STAT+: Cigna, Humana in talks to merge into health insurance giant, per report
Cigna and Humana are in discussions to merge, a potential move that would create a…
STAT+: Biden defends Trump-era drug pricing rule on copay accumulators
WASHINGTON — The Biden administration is appealing a court ruling against a Trump-era regulation that…
U.S. life expectancy rose in 2022, but it remains below its pre-pandemic level
NEW YORK — U.S. life expectancy rose last year — by more than a year…
STAT+: FDA chief scientist to replace Woodcock
WASHINGTON — The Food and Drug Administration’s chief scientist will replace retiring Janet Woodcock as principal…
STAT+: UnitedHealth Group now employs or is affiliated with 10% of all physicians in the U.S.
UnitedHealth Group has about 90,000 employed or affiliated doctors, approximately 10% of all physicians in…
Texas abortion case puts doctors’ agency in treating pregnancy complications in the spotlight
The Texas Supreme Court on Tuesday heard a case that could end up deciding whether…
Flagship Pioneering crosses the pond, opens a European front
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official attacks Bristol over Medicare price talks
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Saudi VC loops Novo Nordisk, other biotech VCs into new longevity incubator
The Hevolution Foundation, a Saudi investment firm focused on aging science, said Wednesday that it…
Opinion: Neuroscience has to grapple with a long legacy of racism if it wants to move into the future
Many parts of neuroscience research have a race problem. Black people are often excluded from…
Opinion: Listen: What we take for granted after 30 years of Prozac
When Prozac first entered the psychiatry scene in in the late ’80s, the profession was…
STAT+: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases
The announcement on Tuesday that the Food and Drug Administration was investigating whether CAR-T immunotherapy…
STAT+: Colon cancer prevention paradox: Higher-risk patients pay more for colonoscopy
Ashley Conway-Anderson was prepared for a lot of things when it came to her first…
STAT+: White House official dings Bristol-Myers Squibb for fighting off generic competition
WASHINGTON — A top White House official on Tuesday delivered a pointed attack at a…
STAT+: Scott Gottlieb, Trump FDA chief, questions whether there’s a Republican philosophy on health care
WASHINGTON — One of the Republican party’s most prominent health care thinkers doesn’t know what…
More colonscopy news and research
A study questioned colonoscopies as the gold standard of colon cancer screens. Then it raised…
STAT+: Biden invokes Cold War-era law to stem drug shortages
WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by…
STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma
The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which…
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
STAT+: Mayo Clinic to spend $5 billion on tech-heavy redesign of its Minnesota campus
Mayo Clinic will spend $5 billion to reinvent its flagship medical campus in Rochester, Minn.,…
Today’s biotech news roundup, in under 800 words
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans
Belgium drugmaker Argenx said Tuesday that its antibody medicine failed to achieve the goals of…
STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs
In response to strained budgets, a growing number of state and local governments across the…
Opinion: Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect
Since the FDA’s approval of lecanemab (marketed as Leqembi) and Medicare’s recent decision to cover…
A nonprofit group is pushing to get estrogen FDA approved for gender-affirming care
Hormone replacement therapies have long been approved by the Food and Drug Administration for use…
How to spot when drug companies spin clinical trial results
Investors, analysts, doctors, and even patients face an avalanche of news from biotech companies about…
STAT+: Springworks wins FDA approval for drug to treat desmoid tumors
The Food and Drug Administration on Monday approved the first treatment for people with desmoid…
STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year…
STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market
Good morning, everyone, and nice to see you again after an extended break on this…
A new algorithm unveils CRISPR ‘treasure trove’
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade
Amid concerns over the use of medically important antibiotics given to food-producing livestock, sales of…
Opinion: The next Census could undercount the number of disabled Americans by 20 million
About 20 million disabled people will be erased if the U.S. Census Bureau moves forward…
New research supports potential link between low-level lead exposure and liver injury
Nearly a decade on, the Flint water crisis still looms large in the minds of…
STAT+: With biotech in a slump, the industry’s job market is upside down
After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra…
STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market
LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with…
Pandemic-related immunity gap in kids explains surge of respiratory infections in children in China, says WHO
Reports this week that China is experiencing a surge in respiratory infections in young children…
Opinion: I grew up in one of Africa’s largest informal settlements. Now I’m helping heal it
I had only lived in Kibera for 15 minutes when I saw a police officer…
Opinion: Hospices can’t handle the growing number of patients who need wound care
A few years ago, I worked with a patient close to 100 years old. She…